GLP-1 & MetabolicFDA ApprovedS

Liraglutide

Victoza / Saxenda

Liraglutide (Victoza for T2D, Saxenda for obesity) is Novo Nordisk's FDA-approved once-daily injectable GLP-1 receptor agonist. SCALE obesity trial demonstrated 5–8% body weight reduction and significant HbA1c reduction. While largely superseded by once-weekly semaglutide and tirzepatide for weight loss, Liraglutide remains a cornerstone type 2 diabetes treatment and has a robust cardiovascular outcomes trial (LEADER) demonstrating cardiovascular risk reduction.

XRedditFacebook
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
Studies cited
6
Research grade
S
Community score
227

Trend index

Trackers
4,658

Overview

About Liraglutide

Liraglutide (Victoza for T2D, Saxenda for obesity) is Novo Nordisk's FDA-approved once-daily injectable GLP-1 receptor agonist. SCALE obesity trial demonstrated 5–8% body weight reduction and significant HbA1c reduction. While largely superseded by once-weekly semaglutide and tirzepatide for weight loss, Liraglutide remains a cornerstone type 2 diabetes treatment and has a robust cardiovascular outcomes trial (LEADER) demonstrating cardiovascular risk reduction.

Category
GLP-1 & Metabolic
Regulatory status
FDA Approved
Also known as
Victoza / Saxenda
Self-reports
6

Community

What 6 users report

6 community reports

Positive 100% · Neutral 0% · Negative 0%

Most reported benefits

Appetite
6

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
2
2000+
4

Commonly stacked with

Research

Cited research (4)

PubMed

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)

Pi-Sunyer et al., 2015

Source
Wiki study page →

Help

Frequently asked

What do PeptIQ users report about Liraglutide?

This page summarizes 6 anonymized self-reports from PeptIQ users who track Liraglutide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.

What research is cited for Liraglutide?

4 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.

Is Liraglutide safe to use?

This wiki does not assess safety or recommend use. Liraglutide is listed as FDA Approved. Consult a licensed clinician for personal medical decisions.

What are the purported benefits and uses of Liraglutide?

Research, primarily in animal models, suggests Liraglutide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.

Source

What is the legal status of Liraglutide?

Liraglutide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Liraglutide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.

Source

What are the known or theoretical side effects and risks of Liraglutide?

The safety and effectiveness of Liraglutide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.

Source

What is the current state of research on Liraglutide?

While there are over 200 published studies on Liraglutide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.

Source